Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations-Reference-Cited by-同舟云学术

Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations

Published:2023 Issue:2 Volume:17 Page:12
ISSN:2036-2579
Container-title:Heart International
language:en
Short-container-title:

Author:

Boutsikos Ioannis,Beltsios Eleftherios,Schmack Bastian,Pantazopoulos Ioannis,Chatzis Dimitrios G, , , , ,

Abstract

Diabetic cardiomyopathy is a well-recognized clinical entity and reflects a complex relationship between metabolic substrates and myocardial function. Sodium glucose co-transporter 2 (SGLT2) inhibitors are antidiabetic agents that are found to exert multiple cardioprotective effects. Large clinical trials showed their beneficial effects on patients with heart failure, reducing the rates of rehospitalizations and improving kidney function. The aim of this review is to summarize the latest evidence in the literature regarding the multiple effects of SGLT2 inhibitors on patients across the spectrum of cardiovascular diseases.

Funder

This article is published under the Creative Commons Attribution Non-commercial License.

Publisher

Touch Medical Media, Ltd.

Subject

Cardiology and Cardiovascular Medicine

Reference104 articles.

1. Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry for the SOLVD investigators. Am J Cardiol. 1996;77:1017–20. DOI: 10.1016/s0002-9149(97)89163-1.

2. Varela-Roman A, Grigorian Shamagian L, Barge Caballero E, et al. Influence of diabetes on the survival of patients hospitalized with heart failure: A 12-year study. Eur J Heart Fail. 2005;7:859–64. DOI: 10.1016/j.ejheart.2005.01.017.

3. Domanski M, Krause-Steinrauf H, Deedwania P, et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol. 2003;42:914–22. DOI: 10.1016/s0735-1097(03)00856-8.

4. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241:2035–8. DOI: 10.1001/jama.241.19.2035.

5. van Melle JP, Bot M, de Jonge P, et al. Diabetes, Glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the heart and soul study. Diabetes Care. 2010;33:2084–9. DOI: 10.2337/dc10-0286.